The Ledger
The bonus system that moves billions of dollars a year to the best-rated Medicare Advantage insurers would be scrapped in randomly chosen states under a proposal the Centers for Medicare & Medicaid Services (CMS) issued Friday. The proposed rule, CMS-4214-P2, would launch ADVaNCE MA, the agency’s first mandatory Medicare Advantage test, a 10-year model that begins in calendar 2029 after a pre-implementation period starting June 8, 2027. In the selected states, “Diamond Ratings” would replace both the Star Ratings and the Quality Bonus Payment system, with plans graded against others in the same state. A new risk-adjustment model would run in shadow mode only. CMS names no states and gives no dollar or savings estimate, so the exposure for any one carrier cannot be sized yet. CMS says it is also considering, but not proposing, a dialysis carve-out. Who it hits: national carriers whose earnings lean on star-linked bonuses, and corporate development teams pricing Medicare Advantage books for 2029 and later. Confidence: High on the terms as CMS states them; Low on financial impact, because CMS gives no figures. Sources: CMS fact sheet on CMS-4214-P2, Federal Register document 2026-23960 as linked by CMS. Supplemental on bonus scale: CNBC.
UPDATE on the star-ratings fight we covered November 18: the same rule would shrink Star Ratings to 15 measures and end the reward factor, while insurers’ lawsuits over the 2027 ratings are still the live fight. CMS proposes dropping the reward factor and narrowing hold-harmless protection for improvement measures to contracts with 4.5 or more stars, with the changes taking effect for the 2030 Star Ratings. It would also change the cut-point method to account for ADVaNCE MA. The fact sheet gives no bonus-dollar estimate. For scale of what the 2027 ratings already moved, Humana said 95 percent of its Medicare Advantage members will be in plans rated four stars or better in 2027, up from about 20 percent in 2026, per reporting by CNBC; those ratings drive 2028 bonus payments. Who it hits: insurers that built 2027 and 2028 budgets around current ratings rules. Confidence: High on the proposed measure changes; Med on the Humana figures, which come from trade and wire reporting, not a filing we opened this run. Sources: CMS fact sheet on CMS-4214-P2. Supplemental: CNBC.
Everis Medical, a Shore Capital Partners-backed maker of ear, nose and throat surgical devices, combined with Hemostasis, a Minnesota sinus-dressing company, in its sixth deal since 2019. The companies announced the combination November 17 and said the merged business will operate as Everis Medical. Hemostasis’ St. Paul facility will keep developing and manufacturing its products, which will still be sold under their existing brand names. Terms were not disclosed. Everis announced its purchase of Hood Laboratories in May, which it described as another addition to its head and neck and airway portfolio. Who it hits: small ENT-device competitors and hospital supply teams that buy from them, as one platform absorbs niche product lines. Confidence: Med. The deal is confirmed by trade reports and the company’s earlier release history, but we could not open the November 17 press release itself. Sources: DBusiness report, Everis Hood Laboratories release.
Quiet note: Saturday is a thin news day for healthcare finance. We found no earnings releases from our watch list, no rating action and no health-system bankruptcy dated November 20 or 21, and we are not repeating the Community Health Systems exchange offer or Redeemer Health case from earlier this week without a new filing.
THE DEAL SHEET
| Target | Acquirer/Investor | Vertical | Value | Source |
|---|---|---|---|---|
| Hemostasis, LLC (St. Paul, Minnesota) | Everis Medical (Shore Capital Partners-backed) | ENT surgical devices | Not disclosed (announced November 17) | DBusiness |
| ATUM (majority investment, completed) | Frazier Healthcare Partners | Bioengineering for drug development | Not disclosed (Business Wire release dated November 17 per its web address; we could not open it) | Hall Render private equity roundup |
No new transactions with announcement dates of November 20 or 21 were spotted in the last 24 hours. The two rows above are from earlier this week and had not been in our Deal Sheet.
Free. One email a day at 6pm your time, or one summary every Friday. Switch or stop anytime.